Abstract:This review comprehensively summarizes the advances in research for fibrosis. It emphasizes organ‐specific profibrotic cell types and molecular mechanisms of fibrosis, especially in the kidney, liver, lung, and heart. The authors highlight the advanced antifibrotic small molecule drugs and cellular therapies for fibrosis. These findings have critical implications for further research and clinical translation of medicine. As the final stage of disease‐related tissue injury and repair, fibrosis is characterized by excessive accumulation of the extracellular matrix. Unrestricted accumulation of stromal cells and matrix during fibrosis impairs the structure and function of organs, ultimately leading to organ failure. The major etiology of fibrosis is an injury caused by genetic heterogeneity, trauma, virus infection, alcohol, mechanical stimuli, and drug. Persistent abnormal activation of "quiescent" fibroblasts that interact with or do not interact with the immune system via complicated signaling cascades, in which parenchymal cells are also triggered, is identified as the main mechanism involved in the initiation and progression of fibrosis. Although the mechanisms of fibrosis are still largely unknown, multiple therapeutic strategies targeting identified molecular mechanisms have greatly attenuated fibrotic lesions in clinical trials. In this review, the organ‐specific molecular mechanisms of fibrosis is systematically summarized, including cardiac fibrosis, hepatic fibrosis, renal fibrosis, and pulmonary fibrosis. Some important signaling pathways associated with fibrosis are also introduced. Finally, the current antifibrotic strategies based on therapeutic targets and clinical trials are discussed. A comprehensive interpretation of the current mechanisms and therapeutic strategies targeting fibrosis will provide the fundamental theoretical basis not only for fibrosis but also for the development of antifibrotic therapies.

Review: Acetylation Mechanisms Andtargeted Therapies in Cardiac Fibrosis.

Review: Acetylation mechanisms and targeted therapies in cardiac fibrosis

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Epigenetic Regulation of Fibroblasts and Crosstalk between Cardiomyocytes and Non-Myocyte Cells in Cardiac Fibrosis

Lipid metabolism reprogramming in cardiac fibrosis

Cardiac Fibrosis: New Insights into the Pathogenesis

Extracellular matrix remodeling and cardiac fibrosis

Targeting Interactions between Fibroblasts and Macrophages to Treat Cardiac Fibrosis

Targeting adipokines: A new strategy for the treatment of myocardial fibrosis

m6A epitranscriptomic and epigenetic crosstalk in cardiac fibrosis

Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies

Acetylation in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction

Construction of cardiac fibrosis for biomedical research

Targeting fibrosis, mechanisms and cilinical trials

Targeting Fibrosis: Mechanisms and Clinical Trials

Targeted inhibition of Focal Adhesion Kinase Attenuates Cardiac Fibrosis and Preserves Heart Function in Adverse Cardiac Remodeling

Fibroblast Diversity and Epigenetic Regulation in Cardiac Fibrosis

Cardiac Fibrosis: Key Role of Integrins in Cardiac Homeostasis and Remodeling

Proteomic Insights into Cardiac Fibrosis: from Pathophysiological Mechanisms to Therapeutic Opportunities